Capricor Therapeutics' Deramiocel demonstrated positive cardiac effects in the HOPE-3 Phase 3 trial for Duchenne muscular dystrophy (DMD), earning the American Heart Association's Outstanding Research Award in Pediatric Cardiology. The trial showed improved heart function and slower progression of heart scarring in treated patients, especially those with cardiomyopathy. These results highlight Deramiocel's potential to address the leading cause of death in DMD patients. Capricor's FDA review is ongoing, with a decision expected by November 22, 2026.
Capricor Therapeutics' Deramiocel cardiac trial results provide context for health sector activity. For readers following health stocks, 110 of 150 US health-sector stocks traded on Pluang rose while 27 fell as of Nov 09, 2026 20:42 WIB. Notable movers include HIMS at USD 24.87 with a -4.35% change and NUWE at USD 4.72 with a +3.06% change.
Neo Security, Inc. has launched Neoverse, a free AI software intelligence engine that researches and classifies over 4 million AI apps, extensions, and servers to assess their capabilities and security risks. Integrated into Neo's platform, Neoverse ...
AnorTech Inc. completed a $7.55 million share exchange with Nasdaq-listed Greenland Mines, increasing Greenland Mines' ownership in AnorTech to 19.9%. Greenland Mines acquired over 25 million AnorTech shares in exchange for Greenland Mines shares val...
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
